香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 進展公告 關連交易 有關出售廣州淘通之股權 及 可能認購杭州天元之股權 茲提 述 復星 國 際有 限公 司 （「本公司 」）日 期 為 2025 年 3 月 14 日及 2025 年 5 月 28 日之公告（「 前 期 公 告 」），内容 有關 復星開心購（ 海南 ）科技有限公司、 黃 震 先生、唐 斌 先 生 、姚宇先生 及 廣州淘通科技股份有限公司 （「廣州淘通 」） 其他 若干現有股東（作為「賣 方 」）與杭州天元寵物用品股份有限公司（「杭 州 天 元 」，作 為買 方，與賣方統稱「訂約方 」）訂立買賣協議 及買賣協議 之 補充協 議（「補充協議 一 」）出 售廣州淘通 之股權。除文義另有所指外，本公告所使用 之詞彙與前 期 公告 所界 定 者具 有 相同 涵義。本 公 告 旨在 提 供有 關 本次交易之 進 一步詳情。 由於 ...

Core Viewpoint - Fosun International announced the sale of 40% equity and voting rights in a target company for €310 million, maintaining a 59.86% stake post-transaction [1] Group 1 - Fosun International's indirect subsidiary Fidelidade is the seller in this transaction [1] - MEIF7 is identified as the buyer in the agreement [1] - The target company will continue to be a subsidiary of Fosun International after the sale [1]

Core Viewpoint - Fosun International (00656.HK) announced the sale of a 40% stake in its subsidiary Luz Saúde, S.A. to MEIF 7 for €310 million, aiming to optimize its capital structure and enhance liquidity [1] Group 1: Transaction Details - The agreement was signed on September 4, 2025 (Lisbon time) [1] - Following the transaction, Fosun will retain 59.86% of the shares and voting rights in Luz Saúde [1] - Luz Saúde is one of the largest private healthcare groups in Portugal, providing a wide range of hospital and clinical services [1] Group 2: Strategic Rationale - The sale aims to optimize the seller's capital structure and improve liquidity [1] - Collaboration with an experienced strategic partner is expected to drive business development and value creation for Luz Saúde while maintaining control over key strategic assets in the healthcare sector [1] - The transaction is designed to strengthen the equity structure, providing better support and momentum for the mid-term growth of Luz Saúde [1]

Core Viewpoint - Fosun International (00656) announced the sale of a 40% stake in Luz Saúde, S.A. for €310 million, aiming to optimize capital structure and enhance liquidity while maintaining control over key strategic assets in the healthcare sector [1] Group 1: Transaction Details - The agreement was signed on September 4, 2025, between Fidelidade (the seller) and MEIF7 (the buyer) [1] - Post-transaction, the seller will hold 59.86% of the shares and voting rights in the target company, which will remain a subsidiary of Fosun International [1] Group 2: Strategic Benefits - The sale is based on three key benefits: 1. Optimizing the seller's capital structure and improving liquidity [1] 2. Collaborating with an experienced strategic partner to drive business development and value creation while retaining control over critical assets in the healthcare sector [1] 3. Strengthening the equity structure to provide stronger support and momentum for the target company's mid-term growth [1] Group 3: Company Background - Luz Saúde, S.A. is one of the largest private healthcare groups in the Portuguese market, offering a wide range of comprehensive hospital and clinical services [1] - As of the announcement date, Luz Saúde is a subsidiary of Fidelidade [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 須予披露交易 有關出售 LUZ SAÚDE, S.A.之股權 出售事項 於 2025 年 9 月 4 日（里斯本時間），Fidelidade（本公司之間接附屬公司，作 為賣方 ） 與 MEIF 7（作為 買方 ） 簽訂協議，據此， 賣方 同意出售及買方同意 購買 目標公司 40%的股 份 及表決權， 基礎 代價為 歐 元 310 百 萬 元。 交 割後 ， 賣方 將持有 目標公司 59.86%的 股份 及表決權，而 目 標公 司 將仍 為本公司的附 屬公司。 MEIF 7（作為買方） 據董事作出一切合理查詢後所深知、盡悉及確信，買方及其最終實益 擁有人均為獨立於本公司及其關連人士之第三方。 排 出售事項的代價應 於交 割 日轉 讓 目標 公司 股 份的 同 時，由買方 以現金 方式 全 額支付。 出售事項的代價 乃經公平磋商後達成，並參考以下因素釐定： (i)目 標公 司 之未 來 發展；(ii)目標公 ...

Core Viewpoint - Fosun International reported a total revenue of 87.3 billion yuan for the first half of 2025, a year-on-year decrease of 10.8% [1] - The group's net profit attributable to shareholders was 660 million yuan, down 8.2% year-on-year [1] Revenue Breakdown - The revenue from the Happiness, Abundance, Health, and Intelligent Manufacturing segments decreased by 21.9%, increased by 3.3%, decreased by 3.0%, and decreased by 24.6%, respectively, totaling 33.72 billion, 27.83 billion, 22.57 billion, and 4.02 billion yuan [1] Insurance Sector Performance - Fosun Portugal Insurance achieved total premium income of 3.27 billion euros, up 16.5% year-on-year, with a market share of 29.3% [1] - The international business premium income was 920 million euros, up 4.3%, accounting for 28.2% of total premium income [2] - The net profit for Fosun Portugal Insurance was 133 million euros, an increase of 27.6% [1] Reinsurance and Health Insurance - Dingrui Reinsurance reported total premiums of 1.06 billion USD, a year-on-year increase of 25.1%, with a net profit of 90 million USD and a ROE of 13.4% [2] - Fosun United Health Insurance achieved total premium income of 3.64 billion yuan, up 31.1% year-on-year, with a net profit of 33 million yuan [2] Wealth Management and Technology - Fosun Wealth Holdings launched the FinRWA Platform, focusing on real-world asset technology and tokenization projects [3] - The team for Star Road Technology consists of professionals from major tech companies, enhancing operational efficiency and development quality [3] Pharmaceutical Sector - Fosun Pharma reported revenue of 19.426 billion yuan, with innovative drug revenue growing by 14.26% to over 4.3 billion yuan [4] - The net profit attributable to shareholders was 1.702 billion yuan, an increase of 38.94% [4] Subsidiary Performance - Yuyuan's revenue decreased by 30.68% to 19.112 billion yuan, with a net profit decline of 94.50% to 63 million yuan [4] - Fosun Tourism's revenue reached a historical high of 9.535 billion yuan, up 1.3% year-on-year, with an operating profit of 1.269 billion yuan, up 22.4% [4] Future Outlook - The company adjusted its revenue forecasts for 2025-2026 to 96 billion and 103.4 billion yuan, respectively, with net profit estimates of 730 million and 930 million yuan [5] - The EPS estimates for 2025-2026 are adjusted to 0.02 and 0.03 yuan, respectively [5]

人民财讯9月4日电，据海南日报，9月3日，海南省省长刘小明在海口会见复星国际联席董事长汪群斌一 行。双方围绕用好海南自贸港政策优势和复星国际行业优势，就推进旅游产品迭代升级、助力国际旅游 消费中心建设，打造矿业一体化产业链、推动新能源产业高质量发展等内容进行交流探讨。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年8月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 復星國際有限公司 | | | 呈交日期: | 2025年9月3日 | | | I. 法定/註冊股本變動 | 不適用 | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00656 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 8,166,558,124 | | 0 | | 8,166,558,124 | | 增加 / 減少 (-) | | | 0 | | ...

Group 1 - Recently, Fosun International successfully issued a total of $400 million in senior unsecured bonds on September 3, showcasing its financing capability in the international market [1][3] - The bonds have a term of 4NC2.5 and a coupon rate set at 6.8%, which is attractive to investors [3] - Standard & Poor's assigned a BB- issuer rating to Fosun International with a stable outlook, enhancing confidence in the bond issuance [3] Group 2 - The funds raised will primarily be used for refinancing part of the existing offshore debt, including payments related to any tender offers [3] - Additional funds will be allocated for the company's working capital and general corporate purposes to support Fosun International's ongoing development [3]

Investment Rating - The investment rating for Fosun International (00656.HK) is "Buy" (maintained) [1] Core Views - The report highlights that Fosun International's revenue for H1 2025 was 87.3 billion HKD, a year-on-year decrease of 10.8%, with a net profit attributable to shareholders of 6.6 billion HKD, down 8.2% year-on-year. The operational profit was 31.5 billion HKD, reflecting a decline of 9.3% primarily due to the performance drop in the Happy segment, particularly from Yuyuan [5] - The report maintains profit forecasts, expecting net profits attributable to shareholders to be 1.23 billion HKD, 1.63 billion HKD, and 1.9 billion HKD for 2025-2027, with year-on-year growth of 32.4% and 17% respectively. The EPS is projected to remain at 0.2 HKD for these years, with the current stock price corresponding to P/E ratios of 32.1, 24.3, and 20.7 times [5] - The report emphasizes the group's focus on asset quality improvement and the deepening of global operations, maintaining a "Buy" rating [5] Financial Summary and Valuation Indicators - Revenue for 2023 is reported at 198.2 billion HKD, with a projected decrease to 192.1 billion HKD in 2024, followed by an increase to 201.7 billion HKD in 2025. The net profit is expected to recover from a loss of 4.35 billion HKD in 2024 to 1.23 billion HKD in 2025 [8] - The gross margin is projected to be 42.8% in 2025, with a net margin of 0.6%. The return on equity (ROE) is expected to be 0.7% in 2025, with an EPS of 0.2 HKD [8] - The report indicates a stable credit rating for the group, with the average debt cost decreasing to 5.3% in H1 2025, down 50 basis points year-on-year [5]